In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Concentrix’s current price at $23.92 is significantly below the PERT-weighted fair value of $215.27, indicating substantial undervaluation with an implied upside of 800%. Despite poor financial health scores, the Monte Carlo analysis shows a high expected value ($516.03) and zero downside scenarios below current price, but with extremely high volatility and risk. Divergence between analyst targets ($52) and DCF/price-sales models highlights varied market expectations.